Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.705 USD | -2.31% | +3.35% | +51.73% |
15/04 | CorMedix's DefenCath Now Commercially Available For US Inpatient Use | MT |
15/04 | CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin) | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.73% | 314M | |
+6.97% | 72.03B | |
-10.86% | 5.14B | |
+46.43% | 4.6B | |
+5.38% | 3.96B | |
-16.20% | 2.5B | |
+21.10% | 2.43B | |
-26.20% | 2.32B | |
+19.92% | 2.18B | |
+8.15% | 1.72B |
- Stock Market
- Equities
- CRMD Stock
- News CorMedix Inc.
- RBC Boosts Price Target on CorMedix to $10 From $6 on 'Heightening Prospects of DefenCath Reaching Market,' Keeps Outperform, Speculative Risk